Individuals carrying GCKR variants that bind to GCK less effectively are characterized by having low fasting plasma glucose levels and protection from chronic kidney disease; however, this is accompanied by an increased risk of nonalcoholic fatty liver disease, hypertriglyceridemia, hyperuricemia, gout, and metabolic syndrome [17,18,19,20,21,22,23,24,25,26]. Here, GCKR is linked to metabolic syndrome.